Bison Wealth LLC Has $12.42 Million Position in Biohaven Ltd. (NYSE:BHVN)

Bison Wealth LLC raised its stake in Biohaven Ltd. (NYSE:BHVN) by 0.4% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 332,428 shares of the company’s stock after buying an additional 1,440 shares during the period. Biohaven makes up about 2.7% of Bison Wealth LLC’s investment portfolio, making the stock its 6th largest holding. Bison Wealth LLC’s holdings in Biohaven were worth $12,416,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently modified their holdings of BHVN. Barclays PLC lifted its holdings in shares of Biohaven by 87.6% during the third quarter. Barclays PLC now owns 268,077 shares of the company’s stock valued at $13,396,000 after purchasing an additional 125,189 shares during the last quarter. Franklin Resources Inc. lifted its stake in Biohaven by 0.5% during the third quarter. Franklin Resources Inc. now owns 79,705 shares of the company’s stock valued at $4,206,000 after buying an additional 412 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Biohaven by 85.4% in the third quarter. JPMorgan Chase & Co. now owns 809,448 shares of the company’s stock worth $40,448,000 after buying an additional 372,737 shares during the period. Diversified Trust Co increased its position in shares of Biohaven by 16.6% in the fourth quarter. Diversified Trust Co now owns 5,585 shares of the company’s stock worth $209,000 after acquiring an additional 795 shares in the last quarter. Finally, Weybosset Research & Management LLC raised its holdings in shares of Biohaven by 23.9% during the fourth quarter. Weybosset Research & Management LLC now owns 13,645 shares of the company’s stock valued at $510,000 after acquiring an additional 2,635 shares during the period. Institutional investors and hedge funds own 88.78% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on BHVN shares. HC Wainwright restated a “buy” rating and issued a $54.00 target price on shares of Biohaven in a report on Tuesday, March 4th. Deutsche Bank Aktiengesellschaft set a $60.00 price objective on Biohaven and gave the stock a “buy” rating in a research report on Thursday, March 20th. William Blair upgraded Biohaven to a “strong-buy” rating in a report on Thursday, April 24th. Morgan Stanley decreased their price target on shares of Biohaven from $69.00 to $63.00 and set an “overweight” rating for the company in a report on Friday, March 7th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $61.00 price objective on shares of Biohaven in a research report on Tuesday, March 4th. Fourteen analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $62.54.

Biohaven Trading Up 0.7 %

Shares of NYSE:BHVN opened at $21.89 on Wednesday. Biohaven Ltd. has a 1 year low of $15.79 and a 1 year high of $55.70. The firm has a fifty day moving average price of $25.73 and a 200 day moving average price of $37.08. The stock has a market capitalization of $2.23 billion, a PE ratio of -2.34 and a beta of 1.33.

Biohaven (NYSE:BHVN) last issued its quarterly earnings data on Monday, March 3rd. The company reported ($1.85) EPS for the quarter, missing analysts’ consensus estimates of ($1.56) by ($0.29). On average, sell-side analysts forecast that Biohaven Ltd. will post -8.9 earnings per share for the current fiscal year.

Insider Buying and Selling at Biohaven

In other Biohaven news, Director John W. Childs purchased 32,700 shares of the stock in a transaction dated Tuesday, March 4th. The shares were bought at an average cost of $30.47 per share, with a total value of $996,369.00. Following the completion of the transaction, the director now owns 2,320,571 shares in the company, valued at $70,707,798.37. This trade represents a 1.43 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 16.00% of the company’s stock.

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.